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Abstract: The treatment for erectile dysfunction (ED) was revolutionized with the development 
of phosphodiesterase type 5 (PDE5) inhibitors. Tadalaﬁ  l (Cialis®; Eli Lilly and Company, 
Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamen-
tarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, 
which lends itself to a longer therapeutic window with on-demand dosing and effective steady-
state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and 
efﬁ  cacy with both dosing strategies for all severities and etiologies of ED, including difﬁ  cult-
to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the 
role of PDE5, and all aspects of tadalaﬁ  l, from its development, through its pharmacology, to 
its latest clinical studies and indications.
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Introduction
Attempts at determining the neurotransmitter or neurotransmitters involved in creating 
an erection may some day lead to successful nonhormonal medical therapy [for erectile 
dysfunction] (Krane 1986, p. 731).
—Robert J Krane, MD, in Campbell’s Urology, Fifth Edition
The last two decades have seen a dramatic growth of understanding in the physiology 
of erection, the pathophysiology of erectile dysfunction (ED), and its treatment options. 
As the above quote from the ﬁ  fth edition of Campbell’s Urology reveals, it was not 
long ago when little was known of erectile physiology, and adequate treatment was 
still “some day” away. Prior to the turn of the century, the pharmacologic treatment 
options for ED were cumbersome and invasive, limited to intracavernosal injections or 
intraurethral pellets. Everything changed when oral phosphodiesterase type 5 (PDE5) 
inhibitors became available, completely revolutionizing the treatment of ED of all 
severities and etiologies. Pﬁ  zer introduced the ﬁ  rst PDE5 inhibitor, sildenaﬁ  l (Viagra®; 
Pﬁ  zer, New York, NY, USA), in March of 1998, and over the past 10 years, the new 
oral pharmacologic therapy together with an unbridled acceptance and newfound 
candor by the general public has not only dramatically increased the awareness and 
prevalence of ED, but also made treatment of the disease simple and effective. Once 
one of the most frustrating and refractory diseases for the urologic specialist, ED is 
now enthusiastically discussed and treated in the primary care setting.
The addition of two more PDE5 inhibitors to the market in 2003 broadened the 
landscape of ED treatment and solidiﬁ  ed PDE5 inhibitors as safe and effective ﬁ  rst-line 
treatments for ED. With the development of the new PDE5 inhibitors, attention was 
focused on increased potency as well as duration of action. Tadalaﬁ  l (Cialis®; Eli Lilly 
and Company, Indianapolis, IN, USA), the newest of the three available PDE5 inhibi-
tors, is similar to sildenaﬁ  l and vardenaﬁ  l (Levitra®; Bayer AG, Germany) in its mecha-
nism of action, but differs primarily in its longer duration of action. In January 2008, Therapeutics and Clinical Risk Management 2008:4(6) 1316
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Eli Lilly announced the latest innovation in the treatment 
of ED, Federal Drug Administration (FDA) approval for 
tadalaﬁ  l once-daily dosing in the treatment of ED.
In this review, we will highlight ED, the physiology of 
penile erection, and the role of PDE5 before focusing on 
the newest and most versatile PDE5 inhibitor. We intend to 
thoroughly report tadalaﬁ  l’s pharmacology, safety, and drug 
interactions; its efﬁ  cacy, indications, and clinical trials; and 
its favorability by patients and partners. The reasons why 
tadalaﬁ  l is a distinct, efﬁ  cacious, and favorable treatment in 
the clinical armamentarium for the treatment of ED will be 
clear at the conclusion of this review.
Erectile dysfunction
ED is the inability to achieve and maintain an erection suf-
ﬁ  cient to permit satisfactory sexual intercourse (NIH 1993). 
Affecting 150 million men worldwide, ED is growing rap-
idly, and its prevalence is expected to double to greater than 
300 million men worldwide over the next 20 years (McKinlay 
2000). According to data extrapolated from the Massachu-
setts Male Aging Study, the incidence of ED is increasing 
at an astronomical rate, with an expected incidence of over 
600,000 new cases per year in white men aged 40 to 69 alone 
(Johannes et al 2000). Despite its growing incidence, which 
is partly a result of the sexual awakening stimulated by the 
new pharmacologic therapies, ED remains underdiagnosed, 
with millions of men worldwide never coming to medical 
attention because of the sensitivity of the issue.
The pathophysiology of ED has a variety of etiologies 
including psychological, hormonal, neurogenic, vasculo-
genic, drug-induced, or cavernosal impairment from any of 
the aforementioned factors (Lue 2000). The etiologies are 
frequently categorized into psychogenic, organic (hormonal, 
neurogenic, vasculogenic, drug-induced, and cavernosal 
impairment), or the most common type of ED which is a 
mixed psychogenic and organic type (Lue 2000).
The pharmacologic evolution that has occurred over the 
past several decades has directed the current understanding of 
the pathophysiology of the disease process. Until the 1980s, 
the treatment options were limited to psychosexual therapy 
and placement of penile implants, and through that time it was 
believed that ED was primarily due to psychogenic causes. 
With the introduction of prostaglandin intracavernosal injec-
tions in the late 1980s, the vasculogenic etiologies of ED 
became better understood, and the connection between late 
onset hypogonadism and ED led to research elucidating the 
hormonal etiologies of the condition (Kaminetsky 2008). 
Finally, the new oral treatment with PDE5 inhibitors has led 
to the current understanding of the pathophysiology of ED 
as well as the physiology of erection.
The physiology of erection 
and the role of phosphodiesterase 
type 5
A penile erection is a transformation of erectile tissue and 
vasculature from a state of minimally-perfused ﬂ  accidity into 
an engorged state. It is mediated by a multifaceted succession 
of neural and vascular components, coupled with hormonal 
and psychological factors. Through complex neural path-
ways consisting of somatic sensory afferent (pudendal) and 
autonomic (cavernous) nerves, as well as supraspinal struc-
tures including the medial preoptic area and paraventricular 
nucleus of the hypothalamus, sexual arousal stimulates the 
release of neurotransmitters that initiate erection (Carson 
and Lue 2005).
The primary erectile-mediating neurotransmitter is nitric 
oxide (NO), a short-lived, gaseous mediator. NO is synthe-
sized in nonadrenergic, noncholinergic fashion by neuronal 
nitric oxide synthase (nNOS) in the cavernous nerves to 
initiate erection and by endothelial nitric oxide synthase 
(eNOS) in the endothelium to maintain erection during sexual 
stimulation (Hurt et al 2002). NO passively crosses the cell 
membrane and activates soluble guanylyl cyclase (sGC) upon 
entering smooth muscle cytoplasm, which in turn increases 
the production of cyclic guanosine monophosphate (cGMP) 
by converting it from guanosine triphosphate (GTP) (Lincoln 
and Cornwell 1991). The increased concentration of cGMP 
activates protein kinase G, also called cGMP-dependent 
kinase, which through phosphorylation of ion channels 
opens potassium channels and inhibits calcium channels. The 
resultant decrease in cytosolic calcium concentration favors 
smooth muscle relaxation (Dean and Lue 2005).
The vascular smooth muscle relaxation simultaneously 
vasodilates arterioles and trabecular smooth muscle sinusoids 
within erectile tissue to increase penile blood ﬂ  ow. Subse-
quently, compression of the subtunical venules against the 
tunica albuginea occludes venous outﬂ  ow. During the ﬁ  nal 
phase of rigid erection, robust contraction of the ischiocav-
ernous muscles constricts the base of the blood-ﬁ  lled corpora 
cavernosa, causing the penis to become even harder. Arterial 
inﬂ  ow and venous outﬂ  ow are temporarily occluded during 
this phase, and the intracavernous pressure can approach 
several hundred millimeters of mercury (Lue 2000).
Detumescence results from sympathetic discharge 
with ejaculation, as well as at the molecular level with 
the cessation of NO release from the endothelium and the Therapeutics and Clinical Risk Management 2008:4(6) 1317
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breakdown of cGMP and other secondary messengers by 
various phosphodiesterase (PDE) enzymes (Lue 2000). 
PDE is an enzyme that 50 years ago was discovered to 
block the activity of the second messenger cyclic adenosine 
3’,5’-monophosphate (cAMP) in animal models (Sutherland 
and Rall 1958). The PDE superfamily includes 11 families, 
PDE1 to PDE11, on 21 unique genes (Lin et al 2003). They 
are distributed throughout various tissues, primarily in 
vascular, visceral, and pulmonary smooth muscle, and they 
regulate physiologic functions in multiple organ systems 
(Carson and Lue 2005). In the penis, PDE acts to breakdown 
cGMP. Despite the observation that every family of PDE 
except PDE6 has been found in the corpus cavernosum, 
PDE5 is the most abundant PDE family in the penis (Carson 
2007). By inhibiting the breakdown of cGMP, PDE5 inhibi-
tors create increased bioavailability of cGMP, which both 
facilitates and potentiates the NO-mediated relaxation of 
erectile smooth muscle with sexual stimulation.
Caffeine and theophylline were two of the ﬁ  rst drugs 
found to inhibit the PDE enzyme decades ago (Butcher and 
Sutherland 1962). Over the past 30 years, inhibitors of several 
families of PDE have been developed to treat a number of 
diseases. These include the PDE3 inhibitors milrinone and 
amrinone developed in the 1980s for heart failure, a PDE4 
inhibitor cilostazol developed for claudication, and the 
anti-platelet drug dipyridamole that inhibits PDE8, PDE9, 
and PDE5 (Carson and Lue 2005). Papaverine was the ﬁ  rst 
PDE inhibitor used in the treatment of ED, and it is still 
used in practice today. Administered as an intracorporal 
injection, papaverine is a non-selective inhibitor of PDE3 
and its isoforms (Carson 2007). Originally investigated as a 
treatment for angina pectoris, the ﬁ  rst oral PDE5 inhibitor, 
sildenaﬁ  l, was fortuitously discovered to produce erections in 
study participants. It was later released in 1998 as the ﬁ  rst oral 
treatment for ED, and this was followed in 2003 by the release 
of two more PDE5 inhibitors, vardenaﬁ  l and tadalaﬁ  l.
History of the development 
of tadalaﬁ  l
The Bothell, Washington-based pharmacologic research 
company ICOS Corporation was started in 1990, and it began 
the initial cardiovascular testing of a PDE5 inhibitor called 
IC351 in 1993. Meanwhile, sildenaﬁ  l citrate (sildenaﬁ  l) 
was discovered to cause improved erectile function as a 
side effect in a trial testing its efﬁ  cacy for the treatment of 
angina pectoris in 1994. IC351 was patented that year, and 
phase I clinical trials began in 1995. Two years later, phase 
II clinical trials began on patients with ED.
The same year that the FDA approved sildenaﬁ  l as the 
ﬁ  rst PDE5 inhibitor for the treatment of ED, Eli Lilly and 
Company joined the ICOS Corporation to form Lilly ICOS 
LLC in 1998 to expand the marketing venture of the newest 
PDE5 inhibitor. Tadalaﬁ  l was ofﬁ  cially born in the year 
2000 when a new drug application was put forth for IC351 
with the generic name tadalaﬁ  l and trade name Cialis.
In May 2002, the ﬁ  rst reports regarding the efﬁ  cacy and 
duration of action of tadalaﬁ  l for ED were presented at the 
97th Annual Meeting of the American Urological Associa-
tion (AUA) in Orlando, Florida, USA. Brock and colleagues 
presented their initial data supporting the efﬁ  cacy and safety 
of tadalaﬁ  l (Brock et al 2002b), and Porst and colleagues 
presented that tadalaﬁ  l is efﬁ  cacious for up to 36 hours (Porst 
et al 2002). Brock’s data were published later that year in a 
landmark integrative analysis of ﬁ  ve randomized controlled 
trials of tadalaﬁ  l that ultimately led to the approval of the 
drug (Brock et al 2002a). Tadalaﬁ  l was approved for use in 
Europe in late 2002, and on November 21, 2003, tadalaﬁ  l 
was approved by the FDA for use in the United States.
Tadalaﬁ  l pharmacology
The three available PDE5 inhibitors share a similar mecha-
nism of action, but they have structural, pharmacologic, and 
clinical differences. The molecular structure of tadalaﬁ  l is 
available in Figure 1. Tadalaﬁ  l’s molecular structure is dif-
ferent than the similar structures of sildenaﬁ  l and vardenaﬁ  l. 
All three have a heterocyclic nitrogen-containing double-
ring system, with a central ring that is analogous to that of 
cGMP and allows for competitive binding of the drug with 
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PDE5 at the catalytic site (Francis et al 2001). Tadalaﬁ  l is 
different in that it is a β-carboline-type PDE5 inhibitor with 
a piperazinedione ring formed from a modiﬁ  cation of the 
hydantoin ring of sildenaﬁ  l (Francis et al 2001).
Phosphodiesterase selectivity
Tadalaﬁ  l is at least 9000 times more selective for PDE5 than 
most of the other families of PDEs, with the exception of 
PDE11 (Briganti et al 2005). PDE11 is found in the testes 
and prostate; however, despite partial inhibition of PDE11 
by tadalaﬁ  l at therapeutic doses, clinical signiﬁ  cance of this 
observation has yet to be fully understood (ICOS 2008). 
A study by Hellstrom and colleagues concluded that there 
are no harmful effects of tadalaﬁ  l on spermatogenesis or 
testicular function (Hellstrom et al 2003).
The PDE enzyme responsible for phototransduction in the 
retina, PDE6, is inhibited to some degree by sildenaﬁ  l and 
vardenaﬁ  l, but not tadalaﬁ  l. The inhibition of PDE6 explains 
the side effect of blue vision experienced by some patients 
with these two drugs, as PDE6 inhibition in the retina causes 
impairment of blue-green color discrimination (Carson 2007). 
Slightly less common with vardenaﬁ  l, altered vision is a 
reported side effect for 11% of men taking sildenaﬁ  l 100 mg 
(Montorsi et al 1999). Compared with sildenaﬁ  l and vardena-
ﬁ  l, tadalaﬁ  l is much less inhibitory for PDE6, and it is over 
700 times more potent for PDE5 than PDE6 (ICOS 2008). For 
this reason, tadalaﬁ  l has less than 0.1% occurrence of vision 
abnormalities (Brock et al 2002; Carson et al 2004a).
Dosing and absorption
Recommended starting doses of tadalaﬁ  l are 10 mg for 
on-demand dosing and 2.5 mg for once-daily dosing, and 
these doses can then be titrated up or down according to 
the efﬁ  cacy and tolerability (ICOS 2008). It is absorbed 
as a low-solubility and high-permeability, or Class 2, drug 
within the FDA Biopharmaceuticals Classiﬁ  cation System 
(Gupta et al 2005). With oral ingestion, after ﬁ  rst-pass 
metabolism, tadalaﬁ  l is approximately 80% bioavailable, 
compared to 40% and 15% with sildenaﬁ  l and vardenaﬁ  l, 
respectively (Francis and Corbin 2003). Tadalaﬁ  l has the 
slowest absorption of the available PDE5 inhibitors with a 
mean of 2 hours to reach its maximum concentration, com-
pared with about 50 minutes for sildenaﬁ  l and vardenaﬁ  l 
(Briganti et al 2005). The onset of action of tadalaﬁ  l may 
occur in as early as 15 minutes of dosing, although successful 
erections occur in fewer than 40% of men at this time point 
(Brock et al 2002; Porst et al 2003). It is not advisable to 
counsel patients that the drug effect may be seen in as early 
as 15 minutes because it may take up to 2 hours for a response 
in the majority of men. This may only create performance 
anxiety or loss of conﬁ  dence in the treatment, leading to 
treatment failure (Carson 2007).
Differences in gastrointestinal absorption with fatty meals 
explain the varying peak plasma concentration (Tmax) among 
the three PDE5 inhibitors (Corbin and Francis 2002). While 
sildenaﬁ  l and vardenaﬁ  l both have decreased absorption 
when taken with a fatty meal, which may increase the rate 
of treatment failure, the absorption of tadalaﬁ  l is unaffected 
by fatty meals or alcohol consumption (Francis and Corbin 
2003). This unique pharmacokinetic trait for tadalaﬁ  l is a 
result of slower absorption and longer half-life, and it can 
therefore be taken with meals or alcohol without a decrease 
in efﬁ  cacy (Carson 2007).
Duration of action
Among the three PDE5 inhibitors, the half-life and thus 
duration of action is the pharmacologic parameter that is 
the most strikingly dissimilar. The half-life of tadalaﬁ  l is 
17.5 hours in normal healthy men and 21.6 hours in elderly 
men, while the half-lives of sildenaﬁ  l and vardenaﬁ  l are 
similar at 4 hours (Francis and Corbin 2003). This longer 
half-life provides a therapeutic window of 36 hours for 
tadalaﬁ  l (Porst et al 2003).
The risks of a longer half-life have yet to be completely 
elucidated, but there does not appear to be any higher mor-
tality with tadalaﬁ  l compared to the other PDE5 inhibitors. 
One difference resulting from the half-life disparity is that 
emergent treatment with nitrate medications must be deferred 
for at least 48 hours after ingestion of tadalaﬁ  l, compared with 
24 hours for sildenaﬁ  l and vardenaﬁ  l (Kloner et al 2003a).
Pharmacologic treatments for ED prior to tadalafil, 
including prostaglandin intracavernosal injections or intra-
urethral pellets, as well as the other two PDE5 inhibitors, 
all have a short half-life. For this reason, historically it has 
been necessary for ED treatments to be dosed immediately 
prior to attempting intercourse. A drawback to this necessary 
dosing schedule for short half-life ED treatments is potential 
performance anxiety. The therapeutic window of 36 hours of 
tadalaﬁ  l allows the patient more freedom to choose the timing 
and setting of the sexual encounter with his partner.
Other beneﬁ  ts of tadalaﬁ  l’s longer half-life are still being 
explored. The FDA recently expanded the indications for 
tadalaﬁ  l to once-daily dosing for the treatment of ED. The 
longer half-life provides a steady state of serum drug concen-
tration with low dose, once-daily administration, a beneﬁ  t not 
shared with the other two PDE5 inhibitors (McMahon 2004; Therapeutics and Clinical Risk Management 2008:4(6) 1319
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McMahon 2005; Porst et al 2006; Porst et al 2008; Rajfer 
et al 2007).
Metabolism and excretion
The metabolism of tadalafil is via the hepatic enzyme 
cytochrome P450 34A (CYP34A) to a catechol metabolite, 
which undergoes further metabolism to its primary circulat-
ing metabolite, methylcatechol glucuronide, a 10,000-fold 
less potent molecule than tadalaﬁ  l (Gupta et al 2005). The 
CYP34A metabolism pathway of tadalafil was verified 
with studies using a CYP34A inhibitor ketoconazole and a 
CYP34A inducer rifampin (Kostis et al 2005). Tadalaﬁ  l is 
excreted largely as metabolites, approximately two-thirds 
into the feces and one-third into the urine (ICOS 2008).
Adverse events
A large study of 2102 men from 11 different multicentered, 
randomized, double-blind, placebo controlled trials of tadala-
ﬁ  l reported the drug is well tolerated overall (Carson et al 
2004a). Fifty-one percent of men using tadalaﬁ  l 20 mg had 
at least one adverse event (AE), but only 3.2% discontinued 
treatment. The most common AEs reported with the 20 mg 
dose were headache (15%), dyspepsia (8%), and back pain 
(5%) (Table 1) (Carson et al 2004a). Most AEs are a result 
of vasodilation of vascular beds other than in the penis.
Although frequently asked about by patients, priapism is 
rarely associated with PDE5 inhibitors. Several case reports 
have found an extraordinarily uncommon link between 
sildenaﬁ  l and priapism, and only a single case report exists 
in the literature implicating tadalaﬁ  l with priapism (King 
et al 2005). PDE5 inhibitors including tadalaﬁ  l may actually 
have some beneﬁ  t in preventing recurrent, or stuttering, 
priapism. A small series of 4 men with stuttering priapism 
were administered daily PDE5 inhibitors, one case of which 
used tadalaﬁ  l, and all four men had decreases in priapism 
recurrences (Burnett et al 2006).
Safety and drug interactions
As with every PDE5 inhibitor, tadalafil is absolutely 
contraindicated with nitrate medications for angina pectoris 
secondary to the potentiated hypotensive effect the drugs can 
have together. Because of the longer half-life, treatment with 
nitrate medications must be deferred for at least 48 hours after 
ingestion of tadalaﬁ  l, compared with 24 hours for sildenaﬁ  l 
and vardenaﬁ  l (Kloner et al 2003a).
The cardiac effects of PDE5 inhibitors have received 
considerable attention because the drugs were originally 
studied as a treatment for angina pectoris secondary to their 
action of smooth muscle relaxation. All of the PDE5 inhibi-
tor trials have tediously monitored study participants’ vital 
signs, particularly heart rate and blood pressure, monitored 
drug effects on cardiac electrophysiology, and tabulated the 
numbers of cardiovascular adverse events (Carson 2005).
In a review of more than 4000 patients from over 60 stud-
ies, data reported by Kloner and co-workers contended that 
tadalaﬁ  l does cause small changes in blood pressure second-
ary to its vasodilatory properties, but that the changes were 
not clinically meaningful (Kloner et al 2003b). In a separate, 
more recent study, the same author retrospectively reviewed 
serious cardiovascular treatment-emergent adverse events 
reported in 36 tadalaﬁ  l trials and found that the incidence of 
these events were comparable among patients taking tadalaﬁ  l 
Table 1 Most common tadalaﬁ  l treatment-emergent adverse events
Safety variable Placebo (n = 638) Tadalaﬁ  l 10 mg (n = 321) Tadalaﬁ  l 20 mg (n = 1143)
Subjects with  1 treatment emergent AE 247 (39%) 185 (58%) 577 (51%)
Discontinuation for AE 8 (1.3%) 5 (1.6%) 36 (3.2%)
Most common treatment emergent AEs
  Headache 30 (5%) 38 (12%) 173 (15%)
  Dyspepsia 7 (1%) 23 (7%) 90 (8%)
  Back pain 15 (2%) 20 (6%) 60 (5%)
  Nasopharyngitis 24 (4%) 26 (8%) 23 (2%)
  Myalgia 6 (1%) 16 (5%) 33 (3%)
  Flushing 8 (1%) 10 (3%) 39 (3%)
  Nasal congestion 4 (1%) 11 (3%) 28 (2%)
  Pain in limb 5 (1%) 10 (3%) 31 (3%)
Data from an integrated analysis of 2102 patients in 11 randomized, double-blind, placebo-controlled trials. Adapted with permission from Carson CC, Rajfer J, Eardley I, et al 
2004a. The efﬁ  cacy and safety of tadalaﬁ  l: an update. BJU Int, 93:1276–81. Copyright © 2004 Wiley-Blackwell.
Abbreviation: AE, adverse events.Therapeutics and Clinical Risk Management 2008:4(6) 1320
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as needed, 3 times per week, once-daily, and placebo (Kloner 
et al 2006).
The Second Princeton Consensus Conference, an 
expert conference on sexual dysfunction and cardiac risk, 
convened in 2004 to develop practice guidelines for the 
management of ED in patients with signiﬁ  cant cardiac 
risk. After reviewing all available literature, the Second 
Princeton Consensus Conference not only determined that 
patients with signiﬁ  cant cardiac risk factors did not exhibit 
worsening ischemia or unstable hemodynamics while tak-
ing PDE5 inhibitors, but also that cardiovascular function 
was actually improved by PDE5 inhibitors in some studies 
(Kostis et al 2005). Although reported with vardenaﬁ  l, pro-
longation of the QTc interval is not observed with tadalaﬁ  l 
(Kloner 2004).
Tadalafil does not cause increased hypotension or 
orthostatic hypotension in men that are also taking multiple 
antihypertensive medications, and it is safe and well tolerated 
in this population (Kloner et al 2003c). The primary excep-
tion is with α-blockers. Frequently prescribed for men with 
benign prostatic hyperplasia (BPH) as well as for men with 
hypertension, α-blockers share a similar mechanism of 
action with PDE5 inhibitors through peripheral vasodila-
tion and may have more of an additive effect than other 
antihypertensives. Recently, the FDA changed its previous 
recommendation from contraindicated co-administration 
to precautionary co-administration (Kostis et al 2005). In 
a study of the blood pressure effects of tadalaﬁ  l coupled 
with either of two α-blockers, doxazosin (Cardura®; Pﬁ  zer, 
New York, NY, USA) and tamsulosin (Flomax®; Boehringer 
Ingelheim, Ridgeﬁ  eld, CT, USA), the hypotensive effect 
of doxazosin was exaggerated by almost 10 mmHg with 
tadalaﬁ  l while there was no change in blood pressure with 
tamsulosin and tadalaﬁ  l (Kloner et al 2004). The authors 
concluded tamsulosin to be a safe α-blocker to administer 
concurrently with tadalaﬁ  l (Kloner et al 2004). Until more 
studies are available, precaution is recommended with the 
co-administration of tadalaﬁ  l with any α-blocker, including 
mixed α-blockers such as labetalol and carvedilol (Kostis 
et al 2005; ICOS 2008).
Because of its metabolism through the cytochrome 
P450 pathway, tadalaﬁ  l is susceptible to changes in serum 
concentration by other drugs that inhibit or promote its 
metabolism. Inhibitors of the CYP34A enzyme include 
ketoconazole, erythromycin, grapefruit juice, and protease 
inhibitors, and co-administration of these drugs with tadalaﬁ  l 
may increase serum concentrations of tadalaﬁ  l. On the con-
trary, co-administration with inducers of CYP34A including 
rifampin, carbamazepine, phenytoin, and phenobarbital, 
would require a larger dose of tadalaﬁ  l for a similar clinical 
effect (Kostis et al 2005).
Efﬁ  cacy
Tadalaﬁ  l is an efﬁ  cacious treatment for ED of all severities 
and etiologies. The largest data series exist for the general 
ED population with mild to moderate ED (Brock et al 2002a; 
Carson et al 2004a), but tadalaﬁ  l has also been shown to be 
an effective treatment for difﬁ  cult-to-treat ED such as more 
severe, organic ED evaluated in tertiary care centers (Carson 
et al 2005a), ED secondary to diabetes mellitus (Saenz de 
Tejada et al 2002; Fonseca et al 2004), and ED resulting from 
prostate cancer treatments such as prostatectomy (Montorsi 
et al 2004; Carson et al 2005b) and radiotherapy (Incrocci 
et al 2007).
Several recent studies have shown a signiﬁ  cant treat-
ment beneﬁ  t from once-daily, low-dose tadalaﬁ  l (McMahon 
2004; McMahon 2005; Porst et al 2006; Rajfer et al 2007; 
Hatzichristou et al 2008; Porst et al 2008). These studies 
have lead to the most recent development in the treatment of 
ED, once-daily tadalaﬁ  l for ED, which was FDA-approved 
in 2008.
Background on outcome measures
Although the effectiveness of PDE5 inhibitors on such 
intermediate objective outcomes as penile rigidity through 
penile plethysmography with the RigiScan device (Dacomed 
Corporation, Minneapolis, MN, USA) has been studied, 
measuring the therapeutic effectiveness of tadalaﬁ  l is more 
accurately deﬁ  ned through an integration of the patient’s 
reported treatment response and tolerability with the reported 
satisfaction of both the patient and his partner (Carson 
et al 2004b). Despite their intrinsically subjective nature, 
validated questionnaires are the preferred major outcome 
measure of treatment effectiveness of tadalaﬁ  l and other 
PDE5 inhibitors.
The International Index of Erectile Function (IIEF) was 
developed by Rosen and colleagues in 1997 as a multidi-
mensional, 15-item, self-administered questionnaire with 
the goal of assessing ﬁ  ve domains of male sexual function 
including erectile function, orgasmic function, sexual desire, 
intercourse satisfaction, and overall satisfaction (Rosen et al 
1997). The erectile function domain of the IIEF (IIEF-EF) 
contains 6 questions which the patient answers on a scale 
from 1 (never or almost never) to 5 (almost always or always), 
providing a total score of 6 to 30 points. The questions 
concern erectile frequency, ﬁ  rmness, penetration ability, Therapeutics and Clinical Risk Management 2008:4(6) 1321
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maintenance frequency, maintenance ability, and erection 
conﬁ  dence (Rosen et al 1997). Based on a controlled study 
of 1151 men taking sildenaﬁ  l in order to establish cutoff 
scores for the IIEF-EF, a score of 26 or greater is deﬁ  ned as 
normal function, mild ED is a score from 22 to 25, mild to 
moderate ED 17 to 21, moderate ED 11 to 16, and severe 
ED 6 to 10 (Cappelleri et al 1999).
The Sexual Encounter Proﬁ  le (SEP) is a patient diary 
that has a series of questions that the patient answers after 
each sexual encounter. The second question in the SEP 
diary (SEP-Q2) is a measure of penetration, “Were you able 
to insert your penis into your partner’s vagina?” The third 
question of the SEP (SEP-Q3) is a true measure of success-
ful intercourse, “Did your erection last long enough for you 
to have successful intercourse?” In tadalaﬁ  l trials including 
data analyses of the SEP, the SEP-Q2 and SEP-Q3 are most 
often reported.
Less often but still occasionally reported in the literature 
is the Erectile Dysfunction Inventory of Treatment Satisfac-
tion (EDITS) score, which more reliably assesses the patient 
and his partner’s satisfaction with ED treatments and explores 
the impact of patient and partner satisfaction on treatment 
continuation (Althof et al 1999). Graded on a scale of 1 to 
100, a score of 50 or higher indicates treatment satisfaction 
(Carson and Lue 2005).
In addition to the IIEF and the SEP, many tadalaﬁ  l trials 
report a global overall assessment as provided by the patient, 
known as a Global Assessment Question (GAQ). It is a sum-
mary question to assess global improvement and to provide 
an indirect estimate of patient satisfaction. A frequently 
reported GAQ in tadalaﬁ  l trials is, “Did the treatment improve 
your erections?”
The general ED population
The most frequently referenced study supporting the efﬁ  cacy 
of tadalaﬁ  l is an integrated analysis of 5 randomized, double-
blind, placebo controlled, multicentered phase III trials from 
1112 men at 74 centers worldwide (Brock et al 2002a). The 
average age was 59, and the etiology of ED was 61% organic, 
9% psychogenic, and 31% mixed. The ED severity at base-
line was mild in 41%, moderate in 23%, and severe in 36%. 
Subjects were randomized to placebo or tadalaﬁ  l at doses 
from 2.5 mg to 20 mg and instructed to self-administer a dose 
before initiating intercourse up to once daily. IIEF-EF, SEP, 
and GAQ scores were assessed at baseline and at 12 weeks 
(Brock et al 2002a).
Results of the integrated analysis found all doses of 
tadalaﬁ  l to enhance efﬁ  cacy outcomes (Brock et al 2002a). 
The IIEF-EF at the end of treatment increased by 6.5 in men 
receiving tadalaﬁ  l 10 mg and by 7.9 with the 20 mg dose, 
compared with 0.6 in men receiving placebo (p   0.001). 
Successful intercourse attempts were increased in 34% of 
men with a 10 mg dose and 39% with a 20 mg dose versus 
a 6% improvement in the placebo group when the SEP-Q3 
answers were compared after 12 weeks (p   0.001). Tadalaﬁ  l 
remained efﬁ  cacious up to 36 hours, as more than 70% of 
attempts were successful from 30 minutes to 36 hours after 
dosing. On the GAQ, 81% of men reported improved erec-
tions overall with tadalaﬁ  l 20 mg compared with 35% in the 
placebo group (p   0.001). The percentage of men receiving 
a 20 mg dose of tadalaﬁ  l who had complete resolution of ED 
as deﬁ  ned by an IIEF-EF of 26 or higher was 59%, compared 
with only 11% with placebo (Brock et al 2002a).
In an update to Brock and colleagues’ study, Carson and 
associates performed another integrated analysis on all avail-
able tadalaﬁ  l trials, including the original 1112 men in the 
5 trials from Brock and colleagues’ original study, plus an 
additional 1215 men from 6 more recently completed trials 
(Carson et al 2004a). The same study design, safety measures, 
and statistical analysis were performed, except patients who 
received 2.5 mg and 5 mg doses in two of the earlier studies 
that were included in the analysis by Brock and colleagues 
were not included by Carson and associates. Only doses of 
10 mg and 20 mg of tadalaﬁ  l were compared with placebo. 
The average age was 56, and the etiology of ED was 58% 
organic, 12% psychogenic, and 31% mixed. The ED severity 
at baseline was mild in 36%, moderate in 27%, and severe in 
33%. Comorbidities included 29% of men with hypertension, 
16% with hyperlipidemia, 20% with diabetes mellitus, and 
5% with coronary artery disease (Carson et al 2004a).
The results from the IIEF-EF, SEP-Q2, and SEP-Q3 are 
summarized in Figure 2. There were robust mean improve-
ments in the IIEF-EF score, with increases of 6.5 points with 
10 mg of tadalaﬁ  l and 8.6 points with the 20 mg dose, versus 
only 0.9 points in the placebo group (p   0.001) (Carson et al 
2004a). According to the SEP-Q3, successful intercourse 
attempts were improved by 34% to a total of 58% with 10 mg 
tadalaﬁ  l, and a 46% improvement to a total of 68% was seen 
with the 20 mg dose, compared with an 8% improvement 
to a 31% total with placebo (p   0.001). When successful 
intercourse attempts with tadalaﬁ  l 20 mg were stratiﬁ  ed by 
time after dosing, tadalaﬁ  l remained almost equally efﬁ  cacious 
at 36 hours. At the endpoint of the trial using the GAQ, 71% 
and 84% of patients reported overall improved erections with 
the two doses of tadalaﬁ  l, respectively, compared with 33% 
with placebo (p   0.001) (Carson et al 2004a). This second Therapeutics and Clinical Risk Management 2008:4(6) 1322
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integrated analysis of 11 tadalaﬁ  l trials concluded that tadala-
ﬁ  l is a very effective and well tolerated treatment for ED of 
all severities and etiologies in men of all ages in the general 
population.
Difﬁ  cult-to-treat ED
In the two trials mentioned in the previous section, the patient 
population was largely a primary care population of relatively 
healthy men with ED of varying severities and etiologies. 
To the contrary, a multicentered, randomized, double-blind, 
placebo controlled trial evaluated how tadalafil 20 mg 
improved ED in men presenting to tertiary care centers with 
more severe, organic ED and with more comorbid medical 
conditions than previous studies (Carson et al 2005a).
One hundred and ninety-ﬁ  ve men were allocated to 
receive tadalaﬁ  l 20 mg or placebo up to once daily for 
12 weeks with simpliﬁ  ed dosing instructions (Carson et al 
2005a). Efﬁ  cacy was assessed using the IIEF-EF, the SEP, 
and a GAQ, and the EDITS was provided at the end of the 
trial to assess satisfaction of the patient and his partner. The 
mean baseline IIEF-EF was 13, with 33% of participants 
reporting mild ED, 23% with moderate ED, and 51% with 
severe ED at baseline. Organic ED predominated with 81%, 
followed by 3% of men with psychogenic ED, and 16% with 
mixed type. Comorbidities included 41% with hypertension, 
36% with hyperlipidemia, 21% with diabetes mellitus, and 
8% with coronary artery disease (Carson et al 2005a).
Tadalaﬁ  l 20 mg improved the IIEF-EF by 6.9 compared 
with −0.2 in the placebo group (p   0.001), improved 
successful intercourse attempts by 34% compared with 4.5% 
in the placebo group (p   0.001), and 73% of patients in 
the tadalaﬁ  l group reported improved erections on the GAQ 
compared with 15% in the placebo group (p   0.001). The 
overall EDITS score was 67 in the tadalaﬁ  l group compared 
with 36 in the placebo group (p   0.001), and a signiﬁ  cant 
correlation was observed between the scores of the patient 
and his partner, demonstrating improved satisfaction with 
parallel improvement in partner satisfaction. This study 
concluded that even in a tertiary care population of patients 
with a higher incidence of severe, organic ED and comorbid 
medical conditions, tadalaﬁ  l remains a safe and well tolerated 
drug that signiﬁ  cantly improves ED treatment satisfaction 
for patients and partners (Carson et al 2005a).
ED secondary to diabetes mellitus
ED is a common problem afﬂ  icting over a third of all men 
with diabetes mellitus type 2, and diabetes is independently 
responsible for a 3- to 4-fold increase in the risk of ED 
according to a survey of 1460 diabetic men (De Barardis et al 
2003). ED is strongly related to the severity of diabetes, with 
a higher incidence in patients with a long history of diabe-
tes, patients using insulin, and patients with microvascular 
complications of diabetes (De Berardis et al 2003). Diabetic 
men with ED also have signiﬁ  cantly worse disease-speciﬁ  c 
health-related quality of life (Penson et al 2003).
In the largest original, prospective trial of tadalaﬁ  l in 
diabetic men, Sáenz de Tejada and co-workers reported 
that tadalaﬁ  l signiﬁ  cantly improves ED and is well tolerated 
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Figure 2 IIEF-EF, SEP-Q2, and SEP-Q3 improvements from baseline to 12 weeks 
with on-demand tadalaﬁ  l.
aErectile function domain score of the International Index of Erectile Function.
bQuestion 2 from the Sexual Encounter Proﬁ  le diary, “Were you able to insert your 
penis into your partner’s vagina?”
cQuestion 3 from the Sexual Encounter Proﬁ  le diary, “Did your erection last long 
enough for you to have successful intercourse?”
*p   0.001 versus placebo.
Data from an integrated analysis of 2102 patients in 11 randomized, double-blind, 
placebo-controlled trials. Adapted with permission from Carson CC, Rajfer J, Eardley I, 
et al 2004a. The efﬁ  cacy and safety of tadalaﬁ  l: an update. BJU Int, 93:1276–81. Copyright 
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in this population (Sáenz de Tejada et al 2002). A total of 
216 men with type 1 or type 2 diabetes mellitus were random-
ized to placebo, tadalaﬁ  l 10 mg, or tadalaﬁ  l 20 mg to be taken 
on-demand up to once daily for 12 weeks. The IIEF-EF, the 
SEP, and a GAQ were used to evaluate efﬁ  cacy. The average 
age was 56, and the duration of diabetes was 12 years on aver-
age. Ninety-one percent of men had type 2 diabetes while 9% 
had type 1 diabetes, 22% had microvascular complications, 
and over 81% of men had poorly controlled diabetes with a 
hemoglobin A1c of greater than 7.0%. The baseline IIEF-EF 
was 12, corresponding to moderate severity ED (Sáenz de 
Tejada et al 2002).
In diabetic men taking tadalaﬁ  l 10 mg or 20 mg, the 
IIEF-EF was improved by 6.4 and 7.3, respectively, com-
pared with 0.1 with placebo (p   0.001) (Sáenz de Tejada 
et al 2002). Successful intercourse was improved by 28% 
and 29% in the two tadalaﬁ  l groups versus only 1.9% in the 
placebo group (p   0.001). The GAQ revealed that only 25% 
of men in the placebo group felt they had improved erec-
tions, compared with 56% and 64% of men in the tadalaﬁ  l 
10 mg and 20 mg groups, respectively (p   0.001) (Sáenz 
de Tejada et al 2002).
Results from a large, retrospective analysis of 12 random-
ized controlled trials of tadalaﬁ  l including over 600 diabetic 
men parallels the data reported by Sáenz de Tejada (Fonseca 
et al 2004). The trials included in this retrospective analysis 
were many of the same trials analyzed in other integrated 
analyses reported here in this review. The average age was 57, 
and diabetic men had more severe ED than patients without 
diabetes at baseline with a mean IIEF-EF of 12.6 compared to 
15 in patients without diabetes (p   0.001). Comorbid condi-
tions more common in the patients with diabetes included 
hypertension, hyperlipidemia, and coronary artery disease 
(Fonseca et al 2004).
Diabetic men in the tadalaﬁ  l 10 mg and 20 mg groups had 
improvements of 6.2 and 7.4 in their IIEF-EF, respectively, 
versus 0.9 for placebo (p   0.001) (Fonseca et al 2004). 
Successful intercourse was improved by 30% and 37% in the 
tadalaﬁ  l 10 mg and 20 mg groups, respectively, compared 
with 4% in the placebo group (p   0.001). Overall, erections 
were reported as improved in 75% for the 20 mg group, 61% 
for the 10 mg group, and 30% for the placebo group (Fonseca 
et al 2004). According to these studies, ED secondary to 
diabetes is certainly amenable to treatment with tadalaﬁ  l.
ED after prostate cancer treatment
All of the available prostate cancer treatments, including 
radical prostatectomy, external beam radiation therapy, 
brachytherapy, cryotherapy, androgen-deprivation therapy, 
and even active surveillance alone, can result in ED. ED 
after prostate cancer treatment includes both organic and 
psychogenic causes, as signiﬁ  cant anxiety and depression 
may result from a diagnosis of prostate cancer, leading to 
psychogenic ED (Carson et al 2005b).
The most important risk for organic ED after prostate can-
cer treatment of any type is damage to the cavernosal nerves. 
Walsh ﬁ  rst described the technique for sparing the bilateral 
neurovascular bundles to better preserve erectile function 
(Walsh et al 1983), and a bilateral nerve sparing radical 
prostatectomy (BNSRP) is the surgical standard for prostate 
cancer today. Approximately 155,000 prostatectomies were 
performed in the United States in 2005 according to hospital 
discharge data (DeFrances 2007). Potency in men after open 
BNSRP has a wide reported range of 10% to 97% in the lit-
erature (Talcott et al 1997; Stanford et al 2000; Walsh et al 
2000; Menon et al 2005; Penson et al 2008). Of 1288 men 
who underwent radical prostatectomy as part of the Prostate 
Cancer Outcomes Study, only 28% had erections sufﬁ  cient 
for intercourse at 5 years (Penson et al 2008).
Cavernosal nerve injury during prostate cancer treatment 
is a neuropraxia resulting in atrophy of the cavernosal smooth 
muscle and abnormal deposition of collagen into the corpora 
cavernosa. Cavernosal hypoxia is another contributing factor 
in the development of ﬁ  brosis post-prostatectomy (Raina 
et al 2008). The smooth muscle atrophy and ﬁ  brosis leads 
to corporal veno-occlusive dysfunction (CVOD), which is 
recognized as the primary cause of organic ED after prostate 
cancer treatment (Rambhatla et al 2008).
There are increasing experimental data that increased 
concentrations of NO and cGMP have an antiﬁ  brotic effect 
on tissues including the tunica albuginea and corporal tissue, 
supporting a role for tadalaﬁ  l to halt the pathophysiologic role 
of CVOD in post-prostate cancer treatment ED. Kovanecz 
and colleagues have recently studied the effect of once-daily 
tadalaﬁ  l on the prevention of ﬁ  brosis and CVOD after cav-
ernosal nerve injury in rats (Kovanecz et al 2007). Male rats 
had either a bilateral cavernosal nerve resection, unilateral 
cavernosal nerve resection, or a sham operation, and they 
were then either untreated or given once-daily tadalaﬁ  l. 
CVOD was assessed at 45 days with cavernosometry and 
histopathology. The authors found that tadalaﬁ  l normalized 
the increase in penile shaft collagen content, normalized the 
reduction in corporeal smooth muscle content, and improved 
the lower collagen type III:I ratio, effectively preventing 
CVOD and underlying corporal ﬁ  brosis after cavernosal 
nerve damage (Kovanecz et al 2008). Similarly, Vignozzi Therapeutics and Clinical Risk Management 2008:4(6) 1324
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et al also found that once-daily tadalaﬁ  l given to rats that 
have undergone bilateral cavernosal nerve resection reversed 
the decline in cavernosal smooth muscle to collagen ratio 
(Vignozzi et al 2006).
In the clinical arena, on-demand dosing of tadalaﬁ  l has 
been studied for ED secondary to BNSRP and external-beam 
radiotherapy (Incrocci et al 2006; Montorsi et al 2004). Mon-
torsi and associates evaluated on-demand dosing of tadalaﬁ  l 
20 mg in men with ED following BNSRP in a randomized, 
double-blind, placebo controlled, multicentered study of 
303 men over 12 weeks (Montorsi et al 2004). All men had 
normal erectile function preoperatively and had undergone 
a BNSRP 12 to 48 months prior to the study. Primary end-
points were IIEF-EF, SEP-Q2, and SEP-Q3, and secondary 
endpoints were the GAQ and the EDITS questionnaire. 
Average age was 60 years, and 93% were white men. Almost 
two-thirds of the participants had some degree of postopera-
tive tumescence at baseline as deﬁ  ned by reporting the ability 
“to achieve at least some erection” in over half of their sexual 
encounters on the SEP-Q1 (Montorsi et al 2004). Among all 
patients, 62% responded to tadalaﬁ  l on the GAQ compared 
with 23% placebo (p   0.001). Of those with some postopera-
tive potency, 71% responded to tadalaﬁ  l compared with 24% 
placebo (p   0.001). The SEP-Q3 revealed 41% of the total 
group had successful intercourse compared with 19% with 
placebo (p   0.001). Over 50% of men with residual func-
tion had successful intercourse compared with 26% placebo 
(p   0.001) (Montorsi et al 2004). In this trial, tadalaﬁ  l was 
successful in producing erections sufﬁ  cient for intercourse in 
men with ED after BNSRP, but it was more efﬁ  cacious in men 
with some residual potency after surgery prior to treatment.
Sixty patients with ED after external-beam radiotherapy 
for prostate cancer were randomized to on-demand tadalaﬁ  l 
20 mg or placebo in a double-blind, placebo controlled, 
crossover study lasting 12 weeks (Incrocci et al 2006). 
Efﬁ  cacy was assessed with the IIEF-EF, SEP, and a GAQ. 
Average age was higher than most other tadalaﬁ  l studies 
at 69 years, the participants’ prostate cancer tumor stages 
were 37% T1c, 37% T2, and 26% T3, and the baseline mean 
IIEF-EF score among all men revealed severe ED at 8.4. The 
IIEF-EF score improved to 17.7 with tadalaﬁ  l and to 9.5 with 
placebo (p   0.0001). The SEP-Q3 data demonstrated 46% 
of participants successfully had intercourse with tadalaﬁ  l 
20 mg compared with 12% with placebo (p   0.0001), and 
67% of patients taking tadalaﬁ  l 20 mg responded positively 
with the GAQ compared with 20% with placebo (p   0.001) 
(Incrocci et al 2006). This study was continued as an open-
label extension over 6 weeks. Fifty-one of 60 patients (85%) 
enrolled, who had a higher IIEF-EF score than those who did 
not enroll (p   0.05). Tadalaﬁ  l was equally effective in the 
double-blind phase as in the open-label phase of the study 
(Incrocci et al 2007).
Tadalaﬁ  l and other PDE5 inhibitors dosed both in con-
tinuous fashion and on-demand have been proposed for 
erectile rehabilitation and ED prophylaxis after BNSRP. 
In a small, prospective, observational study of 27 patients 
who underwent BNSRP, tadalaﬁ  l 20 mg was dosed every 
3 days beginning on the ﬁ  rst postoperative day (Carson 
et al 2005b). At 6 weeks, 89% of men reported erections, 
and 50% had successful intercourse. One-hundred percent 
had erections at 6 months, with 78% reporting successful 
intercourse (Carson et al 2005b). Padma-Nathan and col-
leagues reported in a multicentered, placebo-controlled, 
prospective study of prophylactic sildenaﬁ  l dosed nightly 
beginning 4 weeks after BNSRP and continuing for 
36 weeks that patients taking prophylactic sildenaﬁ  l had a 
27% return of erectile function compared with only 4% in 
the placebo group (p   0.05) (Padma-Nathan et al 2008). 
A randomized, double-blind, multicentered study of early 
postoperative dosing with vardenaﬁ  l, dosed either once-daily 
or on-demand and compared with placebo, in 628 men after 
BNSRP found that on-demand vardenaﬁ  l treatment resulted 
in greater IIEF-EF scores and higher SEP-Q3 response rates 
than once-daily dosing or placebo (Montorsi et al 2008). 
Although the efﬁ  cacy of postoperative treatment with PDE5 
inhibitors to prevent CVOD and corporal ﬁ  brosis and reduce 
ED after BNSRP seems clear, it remains uncertain whether 
a continuous or an on-demand dosing strategy is superior 
in this setting.
Once-daily dosing
The latest innovation in the treatment of ED has arrived in the 
form of a simpler, once-daily dosing schedule for tadalaﬁ  l, 
unlinking the temporal association of the medication and the 
sexual encounter. The unnatural process of taking a medica-
tion just prior to sex is a negative aspect of ED treatment for 
many patients (Hanson-Divers et al 1998). The 17.5 hour 
half-life of tadalaﬁ  l lends itself to daily dosing because 
steady-state plasma concentrations are attained within ﬁ  ve 
days of initiating daily dosing (Forgue et al 2006). Addi-
tionally, at steady-state concentration, the daily exposure 
is 1.6-fold greater than the same dose taken intermittently 
(Forgue et al 2006). Therefore, after 5 days of once-daily 
dosing, the plasma concentration of tadalaﬁ  l achieved with 
a 2.5 mg and 5 mg dose is 4 mg and 8 mg, respectively. The 
FDA announced approval for once-daily dosing of tadalaﬁ  l Therapeutics and Clinical Risk Management 2008:4(6) 1325
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in January 2008 after a thorough review of the studies 
outlined below.
McMahon has compared once-daily with on-demand 
dosing of tadalaﬁ  l in two independent, open-label studies in 
Australian men with ED (McMahon 2004; McMahon 2005). 
In 112 men with ED who were previously unresponsive to 
on-demand tadalaﬁ  l, once-daily tadalaﬁ  l at ﬂ  exible doses 
of 10 mg and 20 mg for 12 weeks was provided (McMahon 
2004). Baseline IIEF-EF, SEP, and GAQ data were obtained 
from the cohort prior to any treatment with tadalaﬁ  l and 
after the trial of on-demand tadalaﬁ  l. Changes in the scores 
from both baselines were assessed after 12 weeks of daily 
dosing. Patients taking tadalaﬁ  l 10 mg once-daily improved 
the IIEF-EF score 12.8 from the no-treatment baseline and 
8.2 from the on-demand treatment baseline (p   0.001). 
Compared with 42% of men with on-demand tadalaﬁ  l, 69% 
of men with once-daily tadalaﬁ  l reported improved erections 
at the endpoint (McMahon 2004). McMahon then compared 
once-daily tadalaﬁ  l 10 mg with on-demand tadalaﬁ  l 20 mg in 
an open-label, parallel-arm, crossover study of 145 Australian 
men with ED (McMahon 2005). While both dosing strategies 
were efﬁ  cacious, the once-daily dosing of tadalaﬁ  l improved 
the IIEF-EF score by 11.9, compared to an improvement of 
8.3 with the on-demand dosing (p   0.05). Additionally, 
compared with 30% at baseline, successful intercourse was 
reported in the SEP-Q3 in 69% and 84% of patients taking 
on-demand and once-daily tadalaﬁ  l, respectively (p   0.05). 
Overall, once-daily dosing was preferred by 72% of the 
patients (McMahon 2005).
The first multicentered, randomized, double-blind, 
placebo controlled study of once-daily tadalaﬁ  l enrolled 
268 men over 12 weeks and compared tadalaﬁ  l 5 mg and 
10 mg taken once-daily with placebo (Porst et al 2006). 
The study took place in 20 centers across Europe and South 
America in men with ED of all severities and etiologies. IIEF-
EF, SEP, and GAQ were assessed at baseline and at 12 weeks. 
The mean IIEF-EF change from baseline at the endpoint was 
9.7 and 9.4 for tadalaﬁ  l 5 mg and tadalaﬁ  l 10 mg, respec-
tively, compared with 0.9 for placebo (p   0.001). Successful 
intercourse was achieved in 67.2% and 72.8%, compared 
with 36.7% with placebo (p   0.001). The authors concluded 
once-daily tadalaﬁ  l 5 mg or 10 mg signiﬁ  cantly improved 
erectile function in men with ED (Porst et al 2006).
Rajfer and associates performed a similar study of 
once-daily tadalaﬁ  l in American men with lower doses 
over a longer study duration (Rajfer et al 2007). Once-daily 
tadalaﬁ  l 2.5 mg, 5 mg, or placebo was dosed over a 24 week 
period in a randomized, double-blind, placebo controlled, 
parallel-design study in 287 men evaluated in 15 US centers. 
Primary endpoints included the change from baseline to 
24 weeks in mean IIEF-EF score and the percentage of “yes” 
responses in SEP-Q2 and SEP-Q3. The IIEF-EF and SEP data 
are summarized in Figure 3. The IIEF-EF score had a mean 
improvement over 24 weeks of 6.0 and 7.0 in the tadalaﬁ  l 
2.5 mg and 5 mg groups, respectively, compared with 1.2 in 
the placebo group (p   0.001). Successful intercourse was 
improved over the 24-week period in 31.2% and 35.1% 
in the tadalaﬁ  l groups compared with 9.5% with placebo 
(p   0.001) (Rajfer et al 2007).
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Figure 3 IIEF-EF, SEP-Q2, and SEP-Q3 improvements from baseline to 24 weeks 
with once-daily tadalaﬁ  l.
aErectile function domain score of the International Index of Erectile Function.
bQuestion 2 from the Sexual Encounter Proﬁ  le diary, “Were you able to insert your 
penis into your partner’s vagina?”
cQuestion 3 from the Sexual Encounter Proﬁ  le diary, “Did your erection last long 
enough for you to have successful intercourse?”
*p   0.001 versus placebo.
Data from a multicenter, randomized, double-blind, placebo-controlled study of 268 
men to study once-daily tadalaﬁ  l over 24 weeks. Adapted with permission from Rajfer 
J, Aliotta PJ, Steidle CP, et al 2007. Tadalaﬁ  l dosed once a day in men with erectile dys-
function: a randomized, double-blind, placebo-controlled study in the US. Int J Impot 
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In open-label extensions of the two randomized, placebo 
controlled trials of once-daily tadalaﬁ  l described above, 
Porst and colleagues have evaluated the long-term safety and 
efﬁ  cacy of once-daily tadalaﬁ  l 5 mg over 1 and 2 years (Porst 
et al 2008). There were 208 of 234 possible patients (88.9%) 
who completed the 1-year extension and 139 of 238 possible 
patients (58.4%) who completed the 2-year extension. Efﬁ  -
cacy was measured by changes in the IIEF-EF score, SEP, 
and the GAQ. The IIEF-EF score improved from baseline by 
10.4 and 10.8 in the 1- and 2-year extensions, respectively. 
After 2 years, 95.7% of patients reported improved erec-
tions (Porst et al 2008). Although an impressively positive 
response, the 2-year GAQ data had a signiﬁ  cant dropout rate 
and likely contained selection bias toward patients who had 
a positive response.
Once-daily tadalafil has recently been studied in a 
population of men with ED secondary to diabetes mellitus 
(Hatzichristou et al 2008). A randomized, double-blind, 
placebo controlled, multicentered study in North America, 
Europe, and Australia enrolled 298 diabetic men with ED 
and randomized them to tadalaﬁ  l 2.5 mg, 5 mg, or placebo 
for 12 weeks. IIEF-EF, SEP, and GAQ were measured as 
primary outcomes. The mean age was 57, 42.6% of patients 
had severe ED, and comorbid conditions were prevalent and 
included 54% with hypertension and 43% with dyslipidemia. 
Eighty-nine percent of patients had diabetes mellitus type 2, 
average hemoglobin A1c was 7.7%, and glycemic control was 
good in 39%, fair in 48%, and poor in 13%. Mean changes 
in IIEF-EF scores were modest, including 4.8 and 4.5 for the 
tadalaﬁ  l 2.5 mg and 5 mg groups, respectively, compared 
with 1.3 for placebo (p   0.005). Successful intercourse was 
improved by 25.9% and 25% in the tadalaﬁ  l groups, versus 
8.2% placebo (p   0.005). In this ﬁ  rst study of once-daily 
tadalaﬁ  l in diabetic men with ED, 2.5 mg and 5 mg once-daily 
both produced modest improvements in erectile function in 
this population (Hatzichristou et al 2008).
New applications
Recent data have indicated a potential association between 
epidemiological, physiologic, pathophysiologic, and treat-
ment aspects of ED and lower urinary tract symptoms 
(LUTS) secondary to BPH (McVary and McKenna 2004). 
The 17.5 hour half-life of tadalaﬁ  l makes it the most suit-
able PDE5 inhibitor for once-daily dosing in a trial of LUTS 
secondary to BPH. McVary and associates reported a mul-
ticentered, randomized, double-blind, placebo controlled 
study of 281 men with LUTS secondary to BPH who 
were randomly assigned to once-daily tadalaﬁ  l 5 mg for 
6 weeks, followed by dose escalation to 20 mg for 6 weeks, 
or 12 weeks of placebo. They reported modest decreases in 
International Prostate Symptom Score (IPSS), with a mean 
change from baseline to 6 weeks of −2.8 with tadalaﬁ  l 5 mg 
versus −1.2 with placebo (p   0.003), and to 12 weeks of −3.8 
with tadalaﬁ  l 5/20 mg versus −1.7 with placebo (p   0.001) 
(McVary et al 2007).
To further examine the efﬁ  cacy and dose response of 
tadalaﬁ  l in men with LUTS secondary to BPH, Roehrborn 
and colleagues performed a similar multicentered, random-
ized, double-blind, placebo controlled study with a larger 
sample size and different tadalaﬁ  l doses (Roehrborn et al 
2008). The 1058 men with LUTS secondary to BPH in the 
study received once-daily placebo or tadalaﬁ  l (2.5, 5, 10 or 
20 mg) for 12 weeks. The IPSS mean change from baseline 
to endpoint after 12 weeks was signiﬁ  cantly improved, –3.9 
for tadalaﬁ  l 2.5 mg (p   0.015), −4.9 for tadalaﬁ  l 5 mg 
(p   0.001), −5.2 for tadalaﬁ  l 10 mg (p   0.001), and −5.2 
for tadalaﬁ  l 20 mg (p   0.001), compared with −2.3 for 
placebo. The optimal risk-beneﬁ  t proﬁ  le for men with LUTS 
secondary to BPH was achieved with the tadalaﬁ  l 5 mg dose 
(Roehrborn et al 2008).
These observations may be a result of increased cGMP 
causing a decrease in prostatic muscle tension (Uckert et al 
2001), NO effect on the smooth muscle of the bladder, PDE 
inhibition in the prostate and prostatic urethra, or some other 
process not yet deﬁ  ned. Further basic science and clinical 
research is necessary to deﬁ  ne the role of tadalaﬁ  l’s effect 
on the bladder, the prostate, and LUTS.
Patient preference
There have been several crossover trials that have attempted 
to compare patient and partner preference between sildenaﬁ  l 
and tadalaﬁ  l. Comparing the PDE5 inhibitors is intrinsically 
difﬁ  cult because of the differences in dosing, absorption, 
duration of action, and other pharmacologic parameters 
(Carson and Lue 2005). Regardless, consensus results across 
multiple studies declare tadalaﬁ  l as preferred over sildenaﬁ  l 
by patients and their partners for the treatment of ED.
In a study to determine the proportion of current sildenaﬁ  l 
users that would switch to tadalaﬁ  l versus resume sildenaﬁ  l 
after given a trial with tadalaﬁ  l, 133 of 147 (90.5%) patients 
elected to switch to tadalaﬁ  l in the extension phase of the 
trial, irrespective of age group, severity of ED, or etiology 
of ED (Ströberg et al 2003). Prospective, randomized studies 
including over 750 men with various severities and etiologies 
of ED have found a preference for tadalaﬁ  l over sildenaﬁ  l by 
signiﬁ  cant margins (Eardley et al 2005; Govier et al 2003; Therapeutics and Clinical Risk Management 2008:4(6) 1327
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von Keitz et al 2004). A randomized, crossover study of 
215 men with ED found 66.3% preferred tadalaﬁ  l over 
sildenaﬁ  l for initiation of ED therapy (Govier et al 2003). 
Another randomized, double-blind, crossover study compar-
ing tadalaﬁ  l with sildenaﬁ  l reported that 132 of 181 (73%) 
chose to receive tadalaﬁ  l during the extension phase of the 
trial, irrespective of previous sildenaﬁ  l use (p   0.001) (von 
Keitz et al 2004). The results were even more disproportion-
ate when stratiﬁ  ed by other comorbid diseases. Men with 
diabetes had an 87% preference for tadalaﬁ  l over sildenail 
(p   0.001), and men with hypertension had a 79% prefer-
ence for tadalaﬁ  l (p   0.001) (von Keitz et al 2004). The 
largest and most recent randomized, crossover, open-label 
study of sildenaﬁ  l and tadalaﬁ  l included 291 men naïve to 
PDE5 inhibitor therapy who were randomized to one drug 
for 12 weeks followed by the other for another 12 weeks, 
with a ﬁ  nal 8-week extension phase during which time the 
patients chose their preferred agent (Eardley et al 2005). 
Efﬁ  cacy of the two drugs was measured by IIEF-EF scores 
and a SEP diary. After completing both treatments, 71% 
men chose tadalaﬁ  l in the extension phase compared to 29% 
sildenaﬁ  l (p   0.001). The IIEF-EF and SEP-Q2 were not 
signiﬁ  cantly different, although the SEP-Q3 measuring suc-
cessful intercourse was 77% with tadalaﬁ  l compared with 
72% with sildenaﬁ  l (p   0.003) (Eardley et al 2005).
The Partner’s Preference Study was a randomized, 
crossover study from a single center comparing tadalaﬁ  l and 
sildenaﬁ  l in 100 couples with the male partner having ED 
(Conaglen and Conaglen 2008). The couples were randomly 
assigned to tadalaﬁ  l or sildenaﬁ  l for 12 weeks followed by a 
second phase with 12 weeks of the alternate drug. Men and 
their partners completed SEP diaries, and the primary out-
come data were the female partners’ ﬁ  nal interviews during 
which they provided their preference between the two drugs. 
Tadalaﬁ  l was preferred by the female partner in 79.2%, while 
15.6% preferred sildenaﬁ  l. The number of events recorded, 
timing of the events, and the number of doses were not sig-
niﬁ  cantly different between the groups. The female partners 
reported more relaxed, more satisfying, and longer-lasting 
sexual experiences with tadalaﬁ  l as compared with sildenaﬁ  l 
(Conaglen and Conaglen 2008).
Conclusion
Tadalaﬁ  l is a safe, well tolerated, and efﬁ  cacious treatment 
for all severities and etiologies of ED. Its efﬁ  cacy has been 
proven in numerous clinical trials, and it is effective not 
only in the general ED population, but also the difﬁ  cult-
to-treat ED population with more severe ED and a greater 
number of comorbidities. Its most unique characteristic is 
its long half-life of 17.5 hours, which lends itself to a longer 
therapeutic window with on-demand dosing and effective 
steady-state plasma concentrations with once-daily dosing. 
Taken on-demand or once-daily, tadalafil significantly 
enhances erectile function. Its newest indication for once-
daily dosing disconnects the temporal association of dosing 
a medication prior to the sexual encounter. These attributes 
make tadalaﬁ  l a distinct, efﬁ  cacious, and favorable treatment 
in the clinical armamentarium for the treatment of ED.
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